ALIPAY+
15.7.2024 09:33:27 CEST | Business Wire | Press release
In a fiercely contested UEFA EURO 2024™, Dani Olmo (Spain), Harry Kane (England), Cody Gakpo (Netherlands), Georges Mikautadze (Georgia), Ivan Schranz (Slovakia), and Jamal Musiala (Germany) emerged as joint winners of the Alipay+ Top Scorer award. Each player scored three goals during the tournament, showcasing exceptional performances throughout and contributing to a memorable event that concluded with a thrilling final at Berlin's Olympiastadion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714542692/en/
Eric Jing, Chairman and CEO of Ant Group, presents the Alipay+ Top Scorer award to the onsite winning football player Dani Olmo of Spain at UEFA EURO 2024™ (Photo: Business Wire)
“Our warmest congratulations to the six exceptional football players for their stellar performances and for winning the Alipay+ Top Scorer award,” said Eric Jing, Chairman and CEO of Ant Group, while presenting the award at the Berlin Olympiastadion. “Just as these athletes push the boundaries of excellence with strength, ingenuity and teamwork, Alipay+ advances global commerce through digital innovation, empowering people and businesses worldwide.”
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International, is the Official Partner of UEFA EURO 2024™. The Alipay+ Top Scorer trophy, sculpted in the shape of the Chinese character “支” (pronounced zhi, meaning payment as well as support), reflects Alipay+’s dedication to supporting consumers to enjoy seamless cross-border payment and access personalised deals when using their preferred payment methods while traveling abroad.
The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that unit people across the world with passion, ambition, and solidarity. The base of the trophy resembles the ocean, consisting of 24 undulating pieces each inscribed with the names of the participating countries, while the design symbolizes the 24 teams braving the waves at the competition. The ocean also connects continents, which represents how football connects communities across the world similar to Alipay+ connecting global commerce.
Alipay+ has now enabled over 400,000 merchants in Europe, with over 120,000 in the DACH region alone. Among the 15 Alipay+ mobile partners in Germany are Alipay (Chinese mainland), AlipayHK (Hong Kong SAR, China), MPay (Macao SAR, China), Touch ’n Go eWallet and MyPB by Public Bank Berhad (Malaysia), Hipay (Mongolia), GCash (The Philippines), OCBC Digital and Changi Pay (Singapore), TrueMoney (Thailand), Tinaba (Italy), Bluecode (Germany and Austria) and Kakao Pay, Naver Pay and Toss Pay (South Korea).
“With Alipay+ and our global partnerships, global fans and visitors explore Germany, Europe and the bigger world seamlessly using their preferred payment methods. Digital commerce connects communities worldwide just like football,” said Jing. “Looking ahead, we are committed to advancing digital technologies for everyone, supporting a robust, inclusive, and sustainable global digital economy.”
About Alipay+
Alipay+ is a suite of cross-border mobile payment and digitalization technology solutions that help connect global merchants to consumers. Consumers enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. Small and medium-sized businesses may use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240714542692/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom